Next-Generation GLP-1 Drugs: Amycretin, Orforglipron, MariTide, and the Pipeline Through 2027
If you thought semaglutide and tirzepatide were the end of the story, the pharmaceutical industry has news for you. What's coming in the next two to three years represents the second wave of the GLP-1 revolution — and it addresses the biggest complaints patients and doctors have about current drugs: weekly injections, GI side effects, the requirement to inject at all, and the cost that keeps these medications out of reach for most of the world. The pipeline includes the first oral small-molecule GLP-1 drug that doesn't require fasting to take, a drug that may need to be injected only once a month, a novel molecule that pairs GLP-1 with a different satiety hormone entirely, and a dual glucagon/GLP-1 drug with weight loss data challenging even tirzepatide. Here's what's coming and why it matters.
Why Innovation Is Accelerating
The market context is staggering. Approximately 2.1 billion adults globally are overweight or obese. Obesity is the second-leading preventable cause of death in the United States and contributes to type 2 diabetes, cardiovascular disease, obstructive sleep apnea, fatty liver disease, and multiple cancers. The first-generation GLP-1 drugs have proven that pharmaceutical intervention can produce clinically meaningful, sustained weight loss at scale.
The limitations of current drugs are also driving innovation:
- Weekly injections: Not all patients are comfortable with self-injection, limiting uptake
- GI side effects: 10–15% of patients discontinue due to nausea and vomiting
- Cost: $1,000+/month in the US without insurance; inaccessible globally at scale
- Partial efficacy: Even on maximum-dose tirzepatide, 20–30% of patients lose less than 10% of body weight
- Injectable-only format: No approved oral option achieves comparable efficacy to injectable versions (yet)
The drugs below represent different engineering approaches to addressing these limitations.
Amycretin (Novo Nordisk): GLP-1 Meets Amylin
What Makes Amycretin Different
Amycretin is not simply a better GLP-1 drug. It is the first unimolecular GLP-1/amylin receptor co-agonist — a single molecule that simultaneously activates GLP-1 receptors and amylin (calcitonin) receptors.
What is amylin? Amylin is a hormone produced by the same beta cells that produce insulin, released alongside insulin after meals. Its physiological role is complementary to GLP-1: it suppresses glucagon, slows gastric emptying, and signals satiety to the brain — but through different neural pathways than GLP-1. The two hormones appear to work synergistically when activated together.
This combination is why amycretin is attracting so much attention. By hitting two complementary satiety pathways simultaneously through one molecule, Novo Nordisk engineers hoped to achieve additive appetite suppression without proportionally adding to side effects.
The comparison to draw is with CagriSema — Novo Nordisk's other combination approach, which pairs semaglutide (GLP-1 RA) with cagrilintide (an amylin analog) as two separate molecules in a single injection. Amycretin takes this further: it's engineered as a single molecule, which may provide different pharmacokinetic and pharmacodynamic properties than two co-injected drugs.
Phase 2 Data: Obesity
Earlier obesity-focused Phase 2 data showed subcutaneous weekly amycretin achieved weight loss of up to 22% over a 36-week dosing period — a number that rivaled tirzepatide's best results and was achieved without the weight loss plateauing at the end of the observation window (suggesting further loss possible with extended treatment).
Phase 2 Data: Type 2 Diabetes (November 2025)
In November 2025, Novo Nordisk announced positive headline results from a Phase 2 trial of amycretin specifically in type 2 diabetes patients — the first evaluation of amycretin in this population. Key findings from 448 participants:
- Subcutaneous amycretin: HbA1c reduction of up to −1.8% from a mean baseline of 7.8%; 89.1% achieving HbA1c <7% at the highest dose
- Oral amycretin: HbA1c reduction of up to −1.5% from a mean baseline of 8.0%; 77.6% achieving HbA1c <7%
- Weight loss (subcutaneous): Up to −14.5% over 36 weeks vs. −2.6% placebo
- Weight loss (oral): Up to −10.1% vs. −2.5% placebo
- No weight loss plateau observed at the highest doses at week 36
Safety profile: consistent with incretin and amylin-based therapies. Most adverse events were GI in nature, mild to moderate.
Based on these results, Novo Nordisk is planning Phase 3 development for amycretin in type 2 diabetes in 2026, following the obesity Phase 3 program initiated in June 2025.
Why It Could Be Best-in-Class
Senior analysts noted that the "absence of a weight loss plateau suggests potential for further improvement with extended treatment, which could challenge current efficacy benchmarks set by tirzepatide." If Phase 3 data confirms 20%+ weight loss with a favorable safety profile in a once-weekly subcutaneous format (with oral formulation also in development), amycretin could represent the next step-change in efficacy — beyond what current GLP-1 dual agonists achieve.
Orforglipron (Eli Lilly): The First True Oral GLP-1
Why This Is a Revolution in Drug Format
Orforglipron is not just another formulation of semaglutide. It is a fundamentally different chemical class: a small-molecule, non-peptide GLP-1 receptor agonist. Every approved GLP-1 medication to date — semaglutide, tirzepatide, liraglutide, dulaglutide — is a peptide: a chain of amino acids that mimics GLP-1's structure. Peptides are destroyed by stomach acid and digestive enzymes, which is why they must be injected.
Orforglipron is chemically simple enough — a small organic molecule, not a peptide — to survive oral ingestion, absorb through the gut wall, and reach the bloodstream intact. It binds to and activates GLP-1 receptors through a different molecular mechanism than peptide agonists but produces similar downstream signaling.
The Crucial Advantage Over Oral Semaglutide (Rybelsus)
Rybelsus, the currently available oral semaglutide, is a peptide in tablet form — which means it still needs special handling. Patients must take it on a completely empty stomach, with a tiny amount of water (≤4 oz), and then wait 30 minutes before eating or taking any other medications. The SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption-enhancing technology allows oral peptide absorption, but only under highly controlled conditions. Even then, bioavailability is far lower than injectable semaglutide.
Orforglipron requires no fasting, no timing restrictions. You take it like an antibiotic — with or without food, at any time. This fundamentally changes adherence: clinical experience with orally dosed medications consistently shows better real-world adherence than injectable equivalents, especially when those injections require self-administration with needles.
ACHIEVE-1 Phase 3 Trial Results (June 2025)
The ACHIEVE-1 trial (adults with type 2 diabetes inadequately controlled on metformin alone) was published in the New England Journal of Medicine at the ADA 2025 Scientific Sessions. Key results at 40 weeks:
- HbA1c reduction: −1.3% to −1.6% depending on dose (vs. placebo), meeting primary endpoint
- Weight loss: Average −16.0 lbs (−7.9%) at the highest dose in key secondary endpoint
- No weight plateau observed, suggesting continued efficacy with longer treatment
- Safety profile consistent with injectable GLP-1 medicines (predominately GI adverse events)
Additionally, the Attain-Maintain Phase 3 trial (December 2025) showed that patients previously treated with Wegovy or Zepbound maintained their weight loss when switched to orforglipron — with participants from Wegovy averaging only 2 lbs difference and participants from Zepbound averaging 11 lbs difference at 52 weeks. This positions orforglipron as a potential step-down maintenance option after injectable induction therapy — a novel use case.
FDA decision: Lilly expects an FDA decision in 2025–2026. Additional Phase 3 trials include ACHIEVE-2 (vs. dapagliflozin) and ACHIEVE-3 (vs. oral semaglutide).
Who This Benefits Most
- Patients with severe needle phobia
- Patients with physically challenging injection access (limited mobility, vision impairment)
- Patients in healthcare systems where injectable medications face greater barriers
- Lower-income patients globally where compounding is not available and injectable cost is prohibitive
- Patients wanting a discreet, pill-form medication without injection-site management
Orforglipron will almost certainly transform GLP-1 market penetration by reaching patient populations currently unreachable with injectables.
MariTide (Maridebart Cafraglutide, Amgen): Monthly or Less Frequent Dosing
The Antibody-Peptide Conjugate Concept
MariTide (formerly AMG 133) is structurally unlike anything else in the GLP-1 space. It is a GLP-1/GIP bispecific antibody-peptide conjugate — a monoclonal antibody backbone with two GLP-1 receptor-activating peptides attached.
Let's unpack that:
- Monoclonal antibody backbone: Antibodies are Y-shaped proteins with very long biological half-lives in the body — typically weeks to months, compared to days for regular peptides. This is what makes infrequent dosing possible.
- GLP-1 activating peptides: Two peptide chains are chemically linked to the antibody, and these activate GLP-1 receptors like standard GLP-1 agonists.
- GIP inhibition: Interestingly, MariTide blocks GIP receptors (inhibits rather than activates them) — the opposite approach from tirzepatide. Preclinical data suggests GIP inhibition may add to weight loss in ways that complement GLP-1 activation, though through different mechanisms than GIP activation. This makes MariTide's mechanism uniquely different from all other drugs in the space.
The antibody format provides two transformative advantages:
- Extended duration: Antibody half-life enables monthly (or potentially less frequent) dosing
- Possible reduced GI side effects: The antibody may provide a different absorption and distribution profile compared to small peptides
ADA 2025 Phase 2 Data (52 Weeks)
Amgen presented full 52-week Phase 2 results at the ADA 2025 Scientific Sessions (June 23, 2025). This was the most anticipated data presentation at the meeting:
In adults with obesity without type 2 diabetes:
- Mean weight loss: 16.3–19.9% (efficacy estimand) at 52 weeks
- Comparison arm (placebo): −2.6%
- No weight loss plateau observed — weight was still declining at week 52
In adults with obesity and type 2 diabetes:
- Mean weight loss: 12.1–17.0% (efficacy estimand) at 52 weeks
- HbA1c reduction: up to −2.2%
- Significant cardiometabolic improvements including reduced CRP and blood pressure
Tolerability: A lower-dose initiation approach (the Phase 1 PK-LDI study) significantly improved tolerability without affecting efficacy — suggesting the final Phase 3 protocol will incorporate this refinement.
Dosing: Monthly subcutaneous administration. Amgen is also exploring less-than-monthly dosing in ongoing studies.
Phase 3 Status: Amgen is initiating Phase 3 MARITIME Chronic Weight Management studies (72-week duration, structured dose escalation), plus Phase 3 outcomes studies for ASCVD, heart failure, and obstructive sleep apnea in 2025.
Why Monthly Dosing Matters
The most common reasons patients miss or discontinue weekly injections: forgetting, injection fatigue, and the psychological burden of weekly self-administration. A medication that needs to be administered monthly eliminates 75% of injections relative to a weekly drug. For chronic disease management, adherence is everything — and monthly dosing represents a fundamental adherence advantage.
Survodutide (Boehringer Ingelheim / Zealand Pharma): Glucagon Added to the Mix
A Different Dual Mechanism
While tirzepatide combines GLP-1 and GIP (both insulinotropic hormones), survodutide (BI 456906) takes a different approach: GLP-1 + glucagon receptor dual agonism. It adds the metabolic effects of glucagon to the appetite-suppressing effects of GLP-1.
This might seem counterintuitive — glucagon raises blood sugar, so why would a diabetes/obesity drug activate the glucagon receptor? The answer lies in glucagon's effects on energy expenditure: glucagon activates brown adipose tissue thermogenesis, increases hepatic fat oxidation, and drives a significant increase in metabolic rate. When combined with GLP-1's appetite suppression, the result is a drug that both reduces calories in (via GLP-1 appetite suppression) and increases calories burned (via glucagon's metabolic stimulation) — potentially addressing the metabolic adaptation problem that blunts weight loss on GLP-1 monotherapy.
Phase 2 Data
In a Lancet Diabetes & Endocrinology 2024 Phase 2 dose-finding trial (46 weeks), survodutide:
- Reduced body weight by up to 12% vs. −0.3% placebo
- More than 55% of participants on the highest dose (4.8 mg) achieved ≥15% weight loss
- Demonstrated greater weight reductions than semaglutide in a head-to-head Phase 2 comparison
A 2024 meta-analysis of 18 treatment arms with 1,029 participants (published in Diabetology & Metabolic Syndrome) confirmed significant weight reduction (WMD: −8.33 kg; 95% CI: −10.80 to −5.86), with longer duration and higher doses producing greater effects.
The tolerability profile was consistent with GLP-1 RAs (predominantly GI adverse events). Phase 3 trials are underway.
Oral Semaglutide (Rybelsus): Already Available, Still Underutilized
Before the fully novel drugs above arrive, it's worth noting that an oral form of semaglutide already exists and is underused. Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes at doses of 3 mg, 7 mg, and 14 mg daily.
| Feature | Rybelsus (Oral Semaglutide) | Orforglipron |
|---|
| Chemistry | Peptide (same molecule as Ozempic) | Small molecule (non-peptide) |
| Fasting required | Yes — 30 min before food, ≤4 oz water | No |
| Maximum dose | 14 mg daily | Higher (36 mg in trials) |
| Bioavailability | ~1% (via SNAC technology) | Higher (true oral absorption) |
| Approved uses | T2D only | T2D; weight management pending |
| Weight loss | Moderate (less than injectable) | Comparable to injectable GLP-1s |
Rybelsus achieves meaningful HbA1c reduction but somewhat less weight loss than injectable semaglutide due to lower bioavailability. For patients who cannot or will not inject, it remains a viable option now — pending the arrival of orforglipron's superior profile.
Comprehensive Pipeline Comparison Table
| Drug | Company | Mechanism | Route | Phase | Best Weight Loss Result | Expected Timeline |
|---|
| Amycretin | Novo Nordisk | GLP-1R + Amylin/CALCR co-agonist | SC weekly + oral | Phase 3 (obesity), Phase 3 (T2D 2026) | ~22% (obesity, 36 wk) | 2027–2028 |
| Orforglipron | Eli Lilly | Oral small-molecule GLP-1R agonist | Oral daily | Phase 3 complete | ~8% at 40 wk (T2D); obesity trials ongoing | 2025–2026 FDA decision |
| MariTide | Amgen | GLP-1R agonist + GIPR antagonist antibody conjugate | SC monthly | Phase 3 initiating | ~20% (obesity, 52 wk) | 2027–2028 |
| Survodutide | Boehringer/Zealand | GLP-1R + Glucagon R dual agonist | SC weekly | Phase 3 | ~12% (46 wk); 55% ≥15% loss | 2026–2027 |
| Oral Semaglutide | Novo Nordisk | GLP-1R agonist (peptide) | Oral daily | Approved | ~14 mg: modest vs. injectable | Available now |
| CagriSema | Novo Nordisk | GLP-1R agonist + Amylin analog (2 molecules) | SC weekly | Phase 3 | ~22% in obesity | 2026–2027 |
| Retatrutide | Eli Lilly | GLP-1R + GIP-R + Glucagon R triple agonist | SC weekly | Phase 3 | ~24% at 48 wk | 2027 |
Market and Access Implications
One of the most important developments in the GLP-1 space is the anticipated effect of competition on pricing. With multiple manufacturers bringing competing products to market between 2025 and 2028, ICER (the Institute for Clinical and Economic Review) and market analysts project significant price pressure.
Key dynamics:
- Oral options will dramatically expand the eligible patient population — many patients who currently decline injectable therapy will accept oral medication
- Monthly-dosed options (MariTide) may command premium pricing for convenience but will also expand adherence
- Generic competition: Semaglutide's composition-of-matter patents expire in the late 2020s (depending on jurisdiction), with generic entry potentially beginning around 2026–2032 in various markets
- Compounded semaglutide: The FDA shortage designations that allowed widespread compounding have created a shadow market that is suppressing branded drug prices indirectly
For patients, the outlook in 2025–2027 is significantly more favorable than 2022–2024: more options, at least one oral non-injection option, and growing insurance coverage as cardiovascular outcome data (SELECT, SURPASS-CVOT) make the medical necessity case more convincingly.
What This Means for Patients in 2025–2027
If you currently inject semaglutide weekly: Orforglipron (if FDA-approved) may offer an oral daily alternative with comparable efficacy and without the fasting requirement of Rybelsus. This is particularly relevant if injection fatigue or compliance is an issue.
If you want maximum weight loss: Amycretin in Phase 3 may surpass even tirzepatide's ~20% ceiling. Keep an eye on Phase 3 results expected 2027.
If adherence to weekly injections is the barrier: MariTide's monthly dosing (entering Phase 3) could be transformative — offering comparable efficacy with 75% fewer injections per year.
If you're newly diagnosed with T2D: The combination of a dual or triple agonist (tirzepatide today, retatrutide or amycretin tomorrow) with SGLT-2 inhibition represents the direction of guideline-based care for most patients with meaningful cardiovascular risk.
If cost is the dominant concern: Competition-driven price decreases, expanding insurance coverage based on SELECT cardiovascular outcome data, and the eventual availability of generic semaglutide are all moving in a favorable direction over the next 2–3 years.
Frequently Asked Questions
Q: What is orforglipron and how is it different from oral semaglutide (Rybelsus)?
A: Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist — chemically completely different from semaglutide. Because it's not a peptide, it's not destroyed by stomach acid and does not require special fasting protocols for absorption. Rybelsus (oral semaglutide) is the same peptide as Ozempic packaged in a tablet using SNAC absorption technology, which requires a 30-minute fasting window and very limited water. Orforglipron can be taken like a regular pill with or without food, which represents a significant practical and adherence advantage.
Q: What is amycretin and what makes it different from semaglutide?
A: Amycretin is a first-in-class unimolecular GLP-1/amylin receptor co-agonist — one molecule that simultaneously activates both GLP-1 receptors and amylin (calcitonin) receptors. Semaglutide activates only GLP-1 receptors. Amylin is a satiety hormone secreted alongside insulin by beta cells, and its activation adds complementary appetite suppression through different brain circuits than GLP-1. Phase 2 data shows up to 22% weight loss in obesity patients — comparable to or exceeding tirzepatide — without plateau at 36 weeks.
Q: What is MariTide and why could monthly dosing change obesity treatment?
A: MariTide (maridebart cafraglutide) is a GLP-1/GIP bispecific antibody-peptide conjugate — a monoclonal antibody backbone with GLP-1 receptor-activating peptides attached. The antibody format gives MariTide a much longer half-life than standard peptides, enabling monthly or even less frequent dosing. Phase 2 data at 52 weeks shows up to ~20% weight loss without plateau. Monthly dosing means 75% fewer injections per year compared to weekly drugs, which could dramatically improve real-world adherence.
Q: What is survodutide and how does its mechanism differ from tirzepatide?
A: Survodutide is a dual GLP-1/glucagon receptor agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist. The key difference: tirzepatide adds GIP signaling (another insulinotropic hormone that enhances beta-cell function and fat metabolism), while survodutide adds glucagon signaling (which increases thermogenesis and fat burning). Glucagon activates brown adipose tissue and increases metabolic rate, potentially addressing the metabolic adaptation (slowing metabolism) that limits long-term weight loss on GLP-1 monotherapy.
Q: When will orforglipron be FDA-approved?
A: Eli Lilly completed Phase 3 ACHIEVE-1 trial results in June 2025, showing significant HbA1c reduction and weight loss. Additional trials (ACHIEVE-2, ACHIEVE-3) are completing in 2025. An FDA decision for the type 2 diabetes indication is anticipated in 2025–2026. The obesity indication (ATTAIN trials) timeline extends slightly later. Approval for the T2D indication could come in 2026.
Q: Does orforglipron cause the same side effects as injectable GLP-1 drugs?
A: In the ACHIEVE-1 Phase 3 trial, orforglipron's safety profile was described as "consistent with injectable GLP-1 medicines" — meaning primarily gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most common, similar to semaglutide and tirzepatide. This is expected since orforglipron activates the same GLP-1 receptors in the gut and brain, producing the same gastric slowing effects. The GI side effect profile may be slightly different in timing due to oral absorption kinetics, but the fundamental adverse effect class is the same.
Q: What is retatrutide and why is it significant?
A: Retatrutide (Eli Lilly) is a triple receptor agonist — GLP-1, GIP, and glucagon receptors all activated by one molecule. Phase 2 data showed approximately 24% weight loss at 48 weeks, the highest reported weight loss for any drug in history. Phase 3 trials are ongoing. If this efficacy translates to the larger Phase 3 trial, retatrutide could represent the most powerful obesity pharmacotherapy available, approaching surgical weight loss outcomes.
Q: Will competition drive down prices for GLP-1 medications?
A: Market analysts and ICER (Institute for Clinical and Economic Review) both project that the increasing number of competing GLP-1 and related drugs entering the market between 2025 and 2028 will put significant downward price pressure on the entire drug class. The entry of orforglipron as an oral option, amycretin as a potentially superior product, and MariTide as a monthly-dosed alternative will create a competitive market. Additionally, generic semaglutide entry (expected late 2020s–early 2030s) will further drive down prices in some markets.
Q: What is the difference between GLP-1/GIP agonism (tirzepatide) and GLP-1/amylin agonism (amycretin)?
A: GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone produced in the small intestine that enhances insulin secretion, supports beta-cell function, and affects adipose tissue metabolism. Amylin is a pancreatic hormone co-secreted with insulin that primarily acts on the brain to suppress appetite and slow gastric emptying. GIP/GLP-1 agonism (tirzepatide) enhances both insulin secretion and metabolic effects. GLP-1/amylin agonism (amycretin) targets two complementary brain appetite circuits simultaneously. The amylin pathway is distinct from GLP-1 and may produce additive satiety signals without proportionally increasing GI side effects.
Q: What is CagriSema and how does it differ from amycretin?
A: CagriSema is a co-injection of two separate molecules: cagrilintide (an amylin analog) and semaglutide (a GLP-1 RA), given as a single weekly injection. It produced approximately 22% weight loss in Phase 2 obesity trials. Amycretin is a single molecule engineered to activate both GLP-1 and amylin receptors — the "unimolecular" approach. Both target the same two receptor systems, but amycretin does so through one compound, potentially offering different pharmacokinetic properties and manufacturing simplicity. Both are in Novo Nordisk's pipeline.
Q: When will the next generation of GLP-1 drugs become available to patients?
A: The timeline for major drugs: Orforglipron — FDA decision anticipated 2025–2026 (T2D indication). Survodutide — Phase 3 ongoing, potential approval 2026–2027. Amycretin — Phase 3 ongoing (obesity), Phase 3 planned 2026 (T2D), potential approval 2027–2028. MariTide — Phase 3 initiating 2025, potential approval 2027–2028. Retatrutide — Phase 3 ongoing, potential approval 2027. Patients will have significantly more options within 2–3 years, including at least one oral non-injection option and eventually a monthly-dosed injectable.
Key Takeaways
- The GLP-1 drug revolution is still accelerating. At least 4–6 novel drugs with superior mechanisms, routes, or dosing intervals will reach Phase 3 completion by 2027.
- Orforglipron (Eli Lilly) is the most immediately impactful innovation: the first oral small-molecule GLP-1 RA that requires no fasting, completing Phase 3 with favorable efficacy and safety — FDA decision expected 2025–2026.
- Amycretin (Novo Nordisk) adds amylin receptor activation to GLP-1, producing up to 22% weight loss in obesity and 14.5% in T2D at 36 weeks — without plateau, suggesting further efficacy with extended treatment.
- MariTide (Amgen) is an antibody-peptide conjugate enabling monthly or less frequent dosing, with up to ~20% weight loss at 52 weeks and no plateau — addressing the adherence burden of weekly injections.
- Survodutide adds glucagon receptor activation to GLP-1, potentially addressing metabolic adaptation by increasing thermogenesis and fat burning — Phase 2 shows 12% weight loss with 55% of highest-dose patients achieving ≥15%.
- Competition from multiple manufacturers is expected to drive prices down significantly by 2027–2028, improving global access.
- The future of obesity medicine is moving toward oral administration, less-frequent dosing, and multi-receptor targeting for increasingly powerful efficacy approaching or matching surgical outcomes.
Citations & References
-
Novo Nordisk Phase 2 Trial with Amycretin in Type 2 Diabetes — Novo Nordisk Press Release (November 2025): https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916463
-
Novo Nordisk Amycretin T2D Phase 2 Success — Clinical Trials Arena (2025): https://www.clinicaltrialsarena.com/news/novo-nordisk-amycretin-t2d-phase-ii-success/
-
Lilly's Oral GLP-1 Orforglipron — Complete Phase 3 Results in NEJM — PR Newswire (June 2025): https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-complete-phase-3-results-published-in-the-new-england-journal-of-medicine-302487392.html
-
Lilly's Orforglipron Phase 3 Superiority — Endocrine News (2026): https://endocrinenews.endocrine.org/lillys-oral-glp-1-orforglipron-demonstrates-superiority-in-phase-3-diabetes-trials/
-
Eli Lilly Orforglipron Attain-Maintain Phase 3 Topline Results — Pharmaceutical Executive (December 2025): https://www.pharmexec.com/view/eli-lilly-announces-topline-results-phase-iii-trial-studying-oral-glp-therapy-orforglipron
-
Amgen MariTide Phase 2 Data at ADA 2025 — Amgen Press Release (June 2025): https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions
-
MariTide Phase II Trial: ADA 2025 Full Summary — DelveInsight: https://www.delveinsight.com/blog/maritide-phase-ii-trial
-
Amgen MariTide 52-Week Data Overview — Medical Update Online (2025): https://medicalupdateonline.com/2025/06/amgen-highlights-52-week-weight-loss-data-for-maritide-and-cardiovascular-outcomes-at-ada-scientific-sessions/
-
Survodutide Reduces Body Weight — Phase 2 Trial Summary: https://pace-cme.org/news/survodutide-reduces-body-weight-phase-2-dose-finding-trial-overweightobesity/2467319/
-
Survodutide Meta-Analysis — Diabetology & Metabolic Syndrome (2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC11542446/
-
Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity — Lancet Diabetes & Endocrinology (2024): https://sio-obesita.org/wp-content/uploads/2025/01/del-prete-2.pdf
